Ligand Pharmaceuticals LGND Increase (Decrease) in Deferred Income Taxes
Increase (Decrease) in Deferred Income Taxes at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredIncomeTaxes.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's increase (decrease) in deferred income taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's increase (decrease) in deferred income taxes?
- Ligand Pharmaceuticals (LGND) reported increase (decrease) in deferred income taxes of $13.53M in Q1 2026.
- How has Ligand Pharmaceuticals's increase (decrease) in deferred income taxes changed year-over-year?
- Ligand Pharmaceuticals's increase (decrease) in deferred income taxes increased by 53.0% year-over-year, from $8.84M to $13.53M.
- What is the long-term trend for Ligand Pharmaceuticals's increase (decrease) in deferred income taxes?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's increase (decrease) in deferred income taxes has grown at a 3.1% compound annual growth rate (CAGR), from -$20.72M to -$22.68M.